Basf Agricultural Solutions Seed US LLC

Bayer Healthcare LLC

Crispr Therapeutics Ag

Bayer Intellectual Property Gmbh

Bayer Pharma Aktiengesellschaft

Basf Se Corporation

Wayne Coco

Jan Tebbe

Michael Strerath

Fabien Poree

Bernd Laber

Gudrun Lange

Ernst Weber

Manuel Dubald

Marc Linka

Nina Wobst

Nikolaus Pawlowski

Heike Balven-Ross

Christina Thies

Sandra Geske

Uwe Gritzan

Christian Votsmeier

Ulrich Haupts

Susanne Steinig

Peter Scholz

Andreas Scheidig

Simone Brückner

Moritz Schmidt

Ashish Gupta

Andre Cohnen

Michael Biag Gamalinda

Kornelia Kirchner

Florian Richter

Kerstin Baral

Christian Pitzler

Klaus Pellengahr

Hanna Plittersdorf

Birgitta Leuthner

Oliver Kensch

Ryo Takeuchi

Markus Rarbach

Christopher J Cheng

Nadine Koch

Cindy Schulenburg

Sabine Jach

Anup Arumughan

Corinna Saalwächter

Caroline W Reiss

Ute Beister

Ulrich Kettling

Ute Solloch

Aspects of this invention, inter alia, relate to novel systems for targeting, editing or manipulating DNA in a cell, using novel synthetic RNA-guided nucleases (sRGNs). The sRGNs are derived from wildtype or parental small type II CRISPR Cas9 endonucleases.

RNA-programmable endonuclease systems and uses thereof

Aspects of this invention inter alia relate to novel systems for targeting, editing or manipulating DNA in a cell, comprising one or more heterologous vector(s) encoding a SluCas9 nuclease fromor variants thereof, and one or more guide RNAs (gRNAs), or a SluCas9 nuclease or variant thereof and one or more gRNAs.

RNA-programmable endonuclease systems and their use in genome editing and other applications

In the present invention, HPPD polypeptides and plants containing them showing a full tolerance against one or more HPPD inhibitor herbicides belonging to various chemical classes are described. A set of mutant HPPD polypeptides have been designed which have either no or only a significantly reduced affinity to HPPD inhibitor herbicides and, at the same time, the rate of dissociation of the HPPD inhibitors of the mutant HPPD polypeptide is increased to such an extent that the HPPD inhibitors no longer act as slow-binding or slow, tight-binding inhibitors but, instead of this, have become fully reversible inhibitors. In particular, isolated polynucleotides encoding mutant HPPD polypeptides conferring tolerance to HPPD inhibitor herbicides belonging to various chemical classes are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed.

HPPD variants and methods of use

Provided herein are antibodies, antigen binding portions, and derivatives thereof that are capable of binding tumor necrosis factor alpha (TNF&#x3b1;); nucleic acids encoding the antibodies, antigen binding portions, and derivatives thereof, including complementary nucleic acids; vectors; and host cells containing the nucleic acids.

Antibodies to TNF&#x3b1;

Growing community of inventors

Pulheim, Germany

Wayne Coco